Vanguard Group
NPCE icon

Vanguard Group’s Neuropace NPCE Stock Holding History

Vanguard Group’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$22.9M Buy
1,482,228
+46,378
+3% +$620K ﹤0.01% 2556
2025
Q3 		$14.8M Buy
1,435,850
+66,574
+5% +$628K ﹤0.01% 2773
2025
Q2 		$15.3M Buy
1,369,276
+171,198
+14% +$2.14M ﹤0.01% 2684
2025
Q1 		$14.7M Buy
1,198,078
+140,783
+13% +$1.76M ﹤0.01% 2638
2024
Q4 		$11.8M Buy
1,057,295
+62,099
+6% +$540K ﹤0.01% 2862
2024
Q3 		$6.94M Buy
995,196
+27,480
+3% +$201K ﹤0.01% 3123
2024
Q2 		$7.32M Buy
967,716
+479,098
+98% +$4.83M ﹤0.01% 3076
2024
Q1 		$6.45M Buy
488,618
+75,512
+18% +$1.08M ﹤0.01% 3188
2023
Q4 		$4.26M Buy
413,106
+27,021
+7% +$215K ﹤0.01% 3346
2023
Q3 		$3.76M Buy
386,085
+7,898
+2% +$46.2K ﹤0.01% 3361
2023
Q2 		$1.7M Buy
378,187
+81,639
+28% +$369K ﹤0.01% 3721
2023
Q1 		$1.38M Buy
296,548
+22,619
+8% +$86.6K ﹤0.01% 3809
2022
Q4 		$408K Buy
273,929
+133
+0% +$295 ﹤0.01% 4156
2022
Q3 		$1.03M Hold
273,796
– – ﹤0.01% 3992
2022
Q2 		$1.35M Sell
273,796
-37,172
-12% -$245K ﹤0.01% 3979
2022
Q1 		$2.55M Sell
310,968
-122
-0% -$1.05K ﹤0.01% 3862
2021
Q4 		$3.13M Buy
311,090
+16,825
+6% +$219K ﹤0.01% 3860
2021
Q3 		$4.66M Buy
294,265
+2,289
+0.8% +$48.1K ﹤0.01% 3708
2021
Q2 		$6.95M Buy
+291,976
New +$6.78M ﹤0.01% 3400

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
KK
Kotler Kevin $427M AUM

Vanguard Group's NPCE Position: Q4 2025 in Review

Vanguard Group increased its Neuropace (NPCE) stake by 3.2% in Q4 2025, buying an estimated $620K and bringing the position to 1,482,228 shares worth $22.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2556.

Vanguard Group first reported a position in NPCE in Q2 2021 and has held it in 19 quarters since. 100 funds tracked by Wall St. Rank hold NPCE as of Q4 2025.

  • Vanguard Group held 1,482,228 shares of Neuropace worth $22.9M as of Q4 2025.
  • Vanguard Group bought 46,378 Neuropace shares in Q4 2025, an estimated $620K.
  • Neuropace made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2556 holding.
  • Vanguard Group first reported a position in Neuropace in Q2 2021 and has held it in 19 quarters since.
  • 100 funds tracked by Wall St. Rank held Neuropace as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.